Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial

Laura Danielle Wagner, Michaela Obersriebnig, Romana Hochreiter, Vera Kadlecek, Julian Larcher‐Senn, Lisa Hegele, Jason D. Maguire, Timothy J. Murphy, Ulla Derhaschnig, Nicole Bézay, Juan Carlos Jaramillo, Susanne Eder-Lingelbach, Marc Messier